Pharmacotherapeutics of SARS-CoV-2 Infections

Kevadiya, Bhavesh D; Machhi, Jatin; Herskovitz, Jonathan; Oleynikov, Maxim D; Blomberg, Wilson R; Bajwa, Neha; Soni, Dhruvkumar; Das, Srijanee; Hasan, Mahmudul; Patel, Milankumar; Senan, Ahmed M; Gorantla, Santhi; McMillan, JoEllyn; Edagwa, Benson; Eisenberg, Robert; Gurumurthy, Channabasavaiah B; Reid, St Patrick M; Punyadeera, Chamindie; Chang, Linda; Gendelman, Howard E

Date

2021-01-06

Journal

Journal of NeuroImmune Pharmacology

Publisher

Springer Nature

Type

Article
Other

Metadata

Show full item record

See at

https://doi.org/10.1007/s11481-020-09968-x

Abstract

The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.].